References
- Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren's syndrome. Lancet. 1994;344(8930):1116–9.
- Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoan-tibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren's syndrome. Transl Res. 2006;148:281–8.
- Nakamura H, Eguchi K, Nakamura T, Mizokami A, Shirabe S, Kawakami A, et al. High prevalence of Sjögren's syndrome in patients with HTLV-I associated myelopathy. Ann Rheum Dis. 1997;56:167–72.
- Hida A, Imaizumi M, Sera N, Akahoshi M, Soda M, Maeda R, et al. Association of human T lymphotropic virus type I with Sjogren syndrome. Ann Rheum Dis. 2010;69:2056–7.
- Nakamura H, Kawakami A, Tominaga M, Hida A, Yamasaki S, Migita K, et al. Relationship between Sjögren's syndrome and human T-Iymphotropic virus type I infection: follow-up study of 83 patients. J Lab Clin Med. 2000;135:139–44.
- Nakamura H, Kawakami A, Hayashi T, Iwamoto N, Okada A, Tamai M, et al. Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord. 2010;11:140.
- Katano K, Kawano M, Koni I, Sugai S, Muro Y. Clinical and laboratory features of anti-centromere antibody positive primary Sjögren's syndrome. J Rheumatol. 2001;28:2238–44.
- Hida A, Kawabe Y, Kawakami A, Migita K, Tominaga M, Nakamura H, et al. HTLV-I associated Sjögren's syndrome is aetiologically distinct from anti-centromere antibodies positive Sjögren's syndrome. Ann Rheum Dis. 1999;58:320–2.
- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alex-ander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.
- Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjö-gren's disease. J Clin Pathol. 1968;21:656–60.
- Beroukas D, Hiscock J, Jonsson R, Waterman SA, Gordon TP. Subcellular distribution of aquaporin 5 in salivary glands in pri-mary Sjögren's syndrome. Lancet. 2001;358: 1875–6.
- Tsuboi H, Matsumoto I, Wakamatsu E, Nakamura Y, Iizuka M, Hayashi T, et al. New epitopes and function of anti-M3 musca-rinic acetylcholine receptor antibodies in patients with Sjögren's syndrome. Clin Exp Immunol. 2010;162:53–61.
- Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-I proviral load in 202 HAM/ TSP patients and 243 asymptomatic HTLV-I carriers: high pro-viral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4:586–93.
- Zhao T, Satou Y, Sugata K, Miyazato P, Green PL, Imamura T, et al. HTLV-1 bZIP factor enhances TGF-13 signaling through p300 coactivator. Blood. 2011;118:1865–76.
- Eguchi K, Matsuoka N, Ida H, Nakashima M, Sakai M, Sakito S, et al. Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis. 1992;51: 769–76.
- Santos SB, Porto AF, Muniz AL, Luna T, Nascimento MC, Guerreiro JB, et al. Modulation of T cell responses in HTLV-1 carriers and in patients with myelopathy associated with HTLV-1. Neuroimmunomodulation. 2006;13:145–51.
- Hansen G, McIntire JJ, Yeung VP, Berry G, 'Thorbecke GJ, Chen L, et al. CD4(±) T helper cells engineered to produce latent TGF-betal reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest. 2000;105: 61–70.
- McCartney-Francis NL, Wahl SM. Dysregulation of IFN-gamma signaling pathways in the absence of TGF-beta 1. J Immunol. 2002;169: 5941–7.